Immunotherapy · 2026
Integrated pharmacological and Omega-3 therapy modulates immunometabolic pathways and neuro-ophthalmological outcomes in relapsing-remitting multiple sclerosis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ahmed Merza Mohammed Tablo, Nouri Shawis Teshk, Ahmad Merza Mohammad Talar, Al-Haideri Maysoon
Аннотация
AIMS: To investigate the immunometabolic and neuro-ophthalmological effects of combined Fingolimod, Metformin, Fluoxetine, and Omega-3 therapy in patients with relapsing-remitting multiple sclerosis (RRMS).
MATERIALS AND METHODS: A total of 80 RRMS patients were analyzed. Peripheral blood mononuclear cells and serum samples were assessed for gene expression of apoptosis- and oxidative stress-related markers (BCL2, BAX, CASP3, NRF2, SOD2, AMPK2), cytokine levels (IL-6, TNF-α, IL-10, IFN-γ), and Th1/Th17 ratio. Optical coherence tomography (OCT) and visual evoked potentials (VEP) were used to evaluate neuro-ophthalmological outcomes.
RESULTS: Omega-3 supplementation was associated with reduced pro-inflammatory cytokines (IL-6, TNF-α) and increased IL-10 levels. It was also linked to higher expression of antioxidant-related genes (NRF2, SOD2, AMPK2) and modulation of T-cell balance, reflected by a reduced Th1/Th17 ratio. Integrated analysis showed distinct clustering of treatment groups, with Omega-3-associated profiles linked to anti-inflammatory and antioxidant signatures. These changes were correlated with improved RNFL thickness and VEP parameters.
CONCLUSIONS: Omega-3 supplementation was associated with coordinated immunometabolic changes and improved neuro-ophthalmological indicators in RRMS patients, suggesting its potential as an adjunct to standard therapies.
MATERIALS AND METHODS: A total of 80 RRMS patients were analyzed. Peripheral blood mononuclear cells and serum samples were assessed for gene expression of apoptosis- and oxidative stress-related markers (BCL2, BAX, CASP3, NRF2, SOD2, AMPK2), cytokine levels (IL-6, TNF-α, IL-10, IFN-γ), and Th1/Th17 ratio. Optical coherence tomography (OCT) and visual evoked potentials (VEP) were used to evaluate neuro-ophthalmological outcomes.
RESULTS: Omega-3 supplementation was associated with reduced pro-inflammatory cytokines (IL-6, TNF-α) and increased IL-10 levels. It was also linked to higher expression of antioxidant-related genes (NRF2, SOD2, AMPK2) and modulation of T-cell balance, reflected by a reduced Th1/Th17 ratio. Integrated analysis showed distinct clustering of treatment groups, with Omega-3-associated profiles linked to anti-inflammatory and antioxidant signatures. These changes were correlated with improved RNFL thickness and VEP parameters.
CONCLUSIONS: Omega-3 supplementation was associated with coordinated immunometabolic changes and improved neuro-ophthalmological indicators in RRMS patients, suggesting its potential as an adjunct to standard therapies.